Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients : week-192 overall and subgroup analyses from STARTMRK
View/ Open
Date
2012Corporate Author(s)
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Medicina Interna. Grupo de Investigación en Enfermedades Infecciosas HUSI - PUJ
Type
Artículo de revista
ISSN
1528-4336 / 1945-5771 (Electrónico)
Pages
228-232
Item type
Reporte de caso
Share this record
Citación
Metadata
Show full item record
PDF documents
Abstract
We compared 4 years of antiretroviral therapy with tenofovir/emtricitabine and either raltegravir or efavirenz from the ongoing STARTMRK study of treatment-naïve HIV- infected patients. Through 192 weeks, raltegravir produced durable and consistent viral suppression and immune restoration compared with efavirenz irrespective of baseline demographic and prognostic factors, including in patients with high viral loads.
Link to the resource
https://www-tandfonline-com.ezproxy.javeriana.edu.co/doi/abs/10.1310/hct1304-228Source
HIV Clinical Trials; Vol. 13 Núm. 4 (2012)
Google Analytics Statistics
Collections
- Artículos [164]